Jim Wassil Sells 1,381 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Key Points

• Vaxcyte EVP Jim Wassil sold 1,381 shares at an average price of $61.16, generating $84,462. The sale reduced his holdings by 0.9% and was made to cover tax withholding tied to vested equity awards.
• Vaxcyte shares recently traded at $59.51, giving the company an $8.86 billion market capitalization. The biotech reported a quarterly loss of $1.97 per share, but surpassed analysts’ expected loss of $2.06.
• Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $86 versus the recent share price. Institutional investors own approximately 96.78% of the company.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 1,381 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $61.16, for a total transaction of $84,461.96. Following the sale, the executive vice president owned 152,228 shares of the company's stock, valued at $9,310,264.48. This trade represents a 0.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Trading Down 1.4%

NASDAQ PCVX traded down $0.85 during trading hours on Wednesday, hitting $59.51. The company's stock had a trading volume of 1,195,242 shares, compared to its average volume of 1,369,661. The company has a market capitalization of $8.86 billion, a PE ratio of -7.80 and a beta of 1.22. Vaxcyte, Inc. has a 52 week low of $30.81 and a 52 week high of $65.00. The company's 50-day simple moving average is $58.41 and its two-hundred day simple moving average is $56.32.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same period in the prior year, the business earned ($1.22) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vaxcyte currently has a consensus rating of "Moderate Buy" and an average price target of $86.00.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors have recently modified their holdings of PCVX. Royal Bank of Canada lifted its holdings in Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock worth $1,113,000 after acquiring an additional 15,774 shares during the period. Cubist Systematic Strategies LLC bought a new position in Vaxcyte in the 1st quarter valued at $219,000. Caxton Associates LLP bought a new position in Vaxcyte in the 1st quarter valued at $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Vaxcyte by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock valued at $19,409,000 after purchasing an additional 41,034 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Vaxcyte by 13.8% during the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company's stock valued at $250,000 after purchasing an additional 932 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.